弥漫大B细胞淋巴瘤预后研究进展：第57届美国血液学会年会报道

Research progress of the prognosis of diffuse large B-cell lymphoma：reports from the 57th American Society of Hematology annual meeting

弥漫大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤类型，具有高度异质性，识别高危患者尤为重要，如何更好地区分判断患者的预后成为第57届美国血液学会（ASH）年会的一大热点。国际预后指数（IPI）作为经典的预后积分系统，其地位不断受到挑战，有多种新的预后积分体系被提出；肿瘤微环境在淋巴瘤进展中起重要作用，其对预后的判断价值也受到越来越多的重视；PET-CT对DLBCL的预后价值在本届会议中也得到进一步肯定。

Diffuse large B-cell lymphoma （DLBCL） is the most common type of non-Hodgkin lymphoma with highly heterogeneous clinical course. How to recognize patients with high risk is coming into the focus of the 57th American Society of Hematology （ASH） annual meeting. The International Prognostic Index （IPI） score as a classic prognostic system is challenged by variety of new prognosis systems. The tumor microenvironment plays an important role in progression of lymphoma, and its prognostic value draw much more attention. The value of PET-CT for prognosis of DLBCL has also been affirmed in this meeting.